Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC

NCT ID: NCT05195294

Last Updated: 2025-03-10

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 55 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-31
• Study Completion Date: 2028-12-31

Brief Summary

This is an open-label and multi-center Phase 2 study to evaluate the safety and efficacy of autologous T-cells transfected with mRNA encoding Hepatitis-B virus (HBV)-antigen-specific T cell receptor (TCR) (LioCyx-M) as monotherapy or as combination with lenvatinib for the treatment of advanced HBV-related hepatocellular carcinoma (HCC).

Conditions

Hepatocellular Carcinoma; Liver Cancer, Adult; Liver Cell Carcinoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

LioCyx-M monotherapy

Patients will receive up to 8 biweekly infusions of HBV antigen specific TCR redirected T cells (LioCyx-M).

Group Type: EXPERIMENTAL

LioCyx-M

Intervention Type: BIOLOGICAL

HBV antigen specific TCR redirected T cells

LioCyx-M + lenvatinib combinational therapy

Patients will receive up to 8 biweekly infusions of HBV antigen specific TCR redirected T cells (LioCyx-M) with daily intake of lenvatinib.

Group Type: EXPERIMENTAL

LioCyx-M

Intervention Type: BIOLOGICAL

HBV antigen specific TCR redirected T cells

Lenvatinib

Intervention Type: DRUG

12 mg once daily for patients ≥60 kg, 8 mg for patients \<60kg by oral

Interventions

LioCyx-M

HBV antigen specific TCR redirected T cells

Intervention Type: BIOLOGICAL

Lenvatinib

12 mg once daily for patients ≥60 kg, 8 mg for patients \<60kg by oral

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1

2. Advanced HCC with diagnosis confirmed by histology/ cytology or clinically by AASLD criteria in cirrhotic patients.

3. Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies

4. Patients who failed first-line systemic therapy for HCC

5. Serum HBsAg positivity

6. Non-cirrhotic or compensated cirrhosis Child-Pugh A (5 - 6 points)

7. HLA class 1 profile matching HLA-class I restriction element of the available T cell receptor

Exclusion Criteria

1. Brain metastasis

2. Second primary malignancy that is clinically detectable at the time of consideration for study enrolment, except for in situ carcinoma of the cervix, non-melanoma skin carcinoma localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer and superficial bladder tumours.

3. Lack of peripheral venous or central venous access or any condition that would interfere with drug administration or collection of study samples

4. History of severe allergic anaphylactic reactions to T cell therapy products and/or lenvatinib

5. Local or loco-regional therapy of intrahepatic tumour lesions (e.g. surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed ≥4 weeks before the first infusion of LioCyx-M.

6. Concurrent administration of any other anti-tumour therapy, including cytotoxic chemotherapy, tyrosine kinase inhibitor therapy, and immunotherapy.

7. Treatment with anticancer therapy, including investigational therapy, within 2 weeks prior to first infusion. For prior therapies with a half-life longer than 3 days, discontinuation of the therapy must have occurred at least 28 days prior to leukapheresis.

8. Treatment with other investigational therapy within 28 days prior to initiation of study treatment. Patients participating in surveys or observational studies are eligible to participate in this study.

9. Likelihood to require any immunosuppressive treatments during the period of the clinical trial (Localized steroid use should be allowed)

10. Human immunodeficiency virus (HIV) positive or active infection requiring treatment (except for HBV)

11. Significant cardiovascular disease (such as New York Heart Association (NYHA) Functional Classification Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment), unstable arrhythmia, or unstable angina

12. Uncontrolled hypertension, defined as systolic blood pressure >160 mmHg or diastolic pressure >110 mmHg, despite optimal medical management

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Lion TCR Pte. Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Regina Wong

Role: CONTACT

regina.wong@liontcr.com

+65 68130738

Other Identifiers

LTCR-HCC-3-4

Identifier Type: -

Identifier Source: org_study_id